Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Peter MacCallum Cancer Centre, Australia: Clinical Trials & FDA Approval Profile

Peter MacCallum Cancer Centre, Australia (Global / Institutional) sponsors 29 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 16 active protocols (5 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)3.5%
Median Closed Enrollment vs National (145 pts)37 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Peter MacCallum Cancer Centre, Australia
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)29
Active Pipeline (Recruiting Now)16 (5)
Completed vs Stopped Early7 / 1 (3.5%)
Median Closed Actual Enrollment37 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Peter MacCallum Cancer Centre, Australia
Hospital Research SiteLocationShared Protocols
Peter MacCallum Cancer CentreMelbourne27
Royal Adelaide HospitalAdelaide, South Australia4
Royal Brisbane and Women's HospitalHerston, Queensland4

Explore interactive annual charts and M&A subsidiary rollups in the Peter MacCallum Cancer Centre, Australia Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI